Overall rank by patents
#31,733
of 49,997 tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Galvanize Therapeutics, Inc.
USPTO PatentsView assignee record - 8 granted patents across 4 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).
The verdict
According to USPTO PatentsView, Galvanize ranks #31,733 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 4 technology areas.
- #31,733
- of 49,997 US assignees by volume
- Top 14%
- by Innovation Score (49.7/100)
- 26.5
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R31733 · US Corporation #31,733 · 8 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 8 grants
- MID-PACK #31,733/49,997
- PHOTO-FINISH Gage Bilt
- CPC-NARROW A61N · 4 areas
- INNOV-PAR 49.7/100
- CLAIMS-DENSE 26.5 claims/avg
- TYPE-USCORP US Corporation
- SPAN-YRS 2022–2025 · 4y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Gage Bilt, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Innovation-score neighbourhood around Galvanize
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Galvanize Therapeutics · this assignee
Galvanize Therapeutics · this assignee
50 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Galvanize's Innovation Score is 49.7/100 (top 14% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Where Galvanize's grants concentrate
Galvanize Therapeutics, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2024. By volume, Galvanize sits between Gummarus, LLC and Garmor Inc..
Galvanize's three-year grant acceleration
Galvanize Therapeutics, Inc. shows 6 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Galvanize's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Gummarus
Gummarus, LLC
8 patents
- Gurtech (PTY)
Gurtech (PTY) Ltd
8 patents
- Gage Bilt
Gage Bilt, Inc.
8 patents
- Gallus Druckmasch…
Gallus Druckmaschinen GmbH
8 patents
- Gangagen
GangaGen, Inc.
8 patents
- Gaplast
Gaplast GmbH
8 patents
- Gardyn
Gardyn Inc.
8 patents
- Garmor
Garmor Inc.
8 patents
- Galvanize Therape… ◀
Galvanize Therapeutics, Inc.
8 patents
What this shows Galvanize holds 8 patents at rank #31,796, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Galvanize
By rank, the assignees closest to #31,796 in granted patent volume.
Leaders in A61N (Electrotherapy)
Other assignees with the most granted patents in Galvanize's primary technology class.
- Medtronic, Inc. 2,200 in class
- Boston Scientific Neuromodulation Corporation 1,080 in class
- Cardiac Pacemakers, Inc. 1,037 in class
- Pacesetter, Inc. 609 in class
- Zoll Medical Corporation 556 in class
- Koniniklijke Philips N.V. 534 in class
- Cochlear Limited 449 in class
- Varian Medical Systems, Inc. 296 in class
Galvanize's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
50 Top 14% higher than 86% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 3 | 37.5% |
| 2023 | 2 | 25.0% |
| 2024 | 1 | 12.5% |
| 2025partial year | 2 | 25.0% |
Which technologies does Galvanize Therapeutics, Inc. patent most?
Top 4 of 4 technology areas
What to do with this data
Galvanize Therapeutics, Inc.'s patent record in context - here's where to go next.
- Galvanize Therapeutics, Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
- Ranked #31,733 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Galvanize Therapeutics, Inc. against Gummarus, LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 49.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.